Page 199 - Haematologica April 2020

Daratumumab in B-NHL
oclonal antibody daratumumab shows antitumor activity and hampers leukemia- microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(6):1493-505.
31. Krejcik J, van de Donk NWCJ. Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. Oncotarget. 2018;9(72):33621-33622.
32. Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on meloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498-7511.
33. Eder T, Eder IE. 3D Hanging drop culture to establish prostate cancer organoids. In: Koledova Z, editor. 3D Cell Culture: Methods and Protocols. New York, NY: Springer New York; p. 167-175.
34. Decaup E, Jean C, Laurent C, et al. Anti- tumor activity of obinutuzumab and ritux- imab in a follicular lymphoma 3D model. Blood Cancer J. 2013;9(3):131.
35. Matas-Céspedes A, Rodriguez V, Kalko SG, et al. Disruption of follicular dendritic cells- follicular lymphoma cross-talk by the pan- PI3K inhibitor BKM120 (Buparlisib). Clin Cancer Res. 2014;20(13):3458-3471.
36. Moros A, Rodríguez V, Saborit-Villarroya I, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant
mantle cell lymphoma. Leukemia. 2014; analysis. Br J Haematol. 2001;114(4):881-
28(10):2049-2059. 883.
37. Campbell KS, Hasegawa J. Natural killer 43. Beers SA, French RR, Chan HT, et al.
cell biology: an update and future direc- Antigenic modulation limits the efficacy of tions. J Allergy Clin Immunol. 2013; anti-CD20 antibodies: Implications for 132(3):536-544. antibody selection. Blood. 2010;
38. Chao MP, Alizadeh AA, Tang C, et al. Anti- 115(25):5191-5201.
CD47 Antibody Synergizes with 44. Beum PV, Peek EM, Lindorfer MA, et al. Rituximab to Promote Phagocytosis and Loss of CD20 and bound CD20 antibody Eradicate Non-Hodgkin Lymphoma. Cell. from opsonized B cells occurs more rapidly 2010;142(5):699-713. because of trogocytosis mediated by Fc
39. Golay J, Lazzari M, Facchinetti V, et al. receptor-expressing effector cells than CD20 levels determine the in vitro suscep- direct internalization by the B cells. J tibility to rituximab and complement of B- Immunol. 2011;187(6):3438-3447.
cell chronic lymphocytic leukemia: further 45. Elhassadi E, Murphy M, Hacking D, Farrell regulation by CD55 and CD59. Blood. M. Durable treatment response of relapsing 2001;98(12):3383-3389. CNS plasmacytoma using intrathecal
40. Vidal L, Gafter-Gvili A, Dreyling MH, et al. chemotherapy, radiotherapy, and Maintenance therapy for Patients with Daratumumab. Clin Case Rep. 2018; mantle cell Lymphoma (MCL) - a systemat- 6(4):723-728.
ic review and meta-analysis of randomized 46. Touzeau C, Moreau P. How I treat controlled trials (RCTs). Blood. 2016; extramedullary myeloma. Blood. 2016; 128(22):1802. 127(8):971-976.
41. Vidal L, Gafter-Gvili A, Salles G, et al. 47. Pallasch CP, Leskov I, Braun CJ, et al. Rituximab maintenance improves overall Sensitizing protective tumor microenviron- survival of patients with follicular lym- ments to antibody-mediated therapy. Cell. phoma-Individual patient data meta-analy- 2014;156(3):590-602.
sis. Eur J Cancer. 2017;76216-76225. 48. Tosolini M, Algans C, Pont F, Ycart B 42. Foran JM, Norton AJ, Micallef IN, et al. Fournié JJ. Large-scale microarray profiling Loss of CD20 expression following treat- reveals four stages of immune escape in ment with rituximab (chimaeric monoclon- non-Hodgkin lymphomas.
al anti-CD20): A retrospective cohort Oncoimmunology. 2016;5(7):e1188246.
haematologica | 2020; 105(4)
1041